Project Grant R21OD034470
- The National Institutes of Health's National Center for Advancing Translational Sciences (NCATS) awarded a $145,636 project grant (CFDA 93.350) to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to evaluate the relationship between thyroid hormone levels and brown adipose tissue activity, transcriptome, and cellular composition in adult humans. The study aims to better understand the interaction between the thyroid axis and brown adipose tissue in the process of thermogenesis and energy...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $462,923 to Albany Medical College to develop new mouse models of andropause (age-related decline in male sex hormones) for Alzheimer's disease and related dementia (ADRD) research. The primary goals are to: Determine the natural time course of endocrine aging in wild-type mice and mouse models of ADRD (Aim 1). Model endocrine aging in male mice via gonadectomy and gradual androgen...
- This $529,650 federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) supports the development and validation of a novel thermal imaging-based platform called ENTICE. The platform is designed to longitudinally record and analyze groups of young, middle-aged, and old mice to determine age-related changes in physical activity energy expenditure (PAEE) and other components of total energy expenditure (TEE). The goal is to uncover common determinants...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,283,334.00 to the Morehouse School of Medicine (MSM) to develop and validate a progressive mouse model for Traumatic Brain Injury-related Alzheimer's Disease and Related Dementias (TBI-ADRD). The project aims to systematically screen mouse strains and TBI injury types to identify the optimal model for recapitulating key neuropathological, neurobiochemical, and neurocognitive features of human...
- Project Grant Summary The University of Michigan, through its Office of Research and Sponsored Projects, received a $1.73M Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) to conduct genetic research on cognitive outcomes related to caloric restriction. The award, effective March 1, 2026 through January 31, 2031, funds a comprehensive research initiative utilizing the Diversity Outbred (DO) mouse model—a systems genetics resource designed to...
- Federal Project Grant Award Summary Boston University Medical Campus received a $817,498 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective February 18, 2026 through January 31, 2031. The research focuses on investigating vasculature and beige remodeling of obese adipose tissue to develop therapeutic strategies for obesity and metabolic...
- This Project Grant award for $399,187 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support Virginia Commonwealth University's research to develop novel genetically engineered mouse models to study the development of marginal zone lymphomas (MZL). The research aims to 1) investigate the impact of activation of the PI3K/AKT/mTOR pathway on MZL development, and 2) determine optimal drug combinations for targeting this pathway in MZL. This work seeks to establish...
- Federal Project Grant Award Summary Cincinnati Children's Hospital Medical Center received a $771,701 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), with an award date of June 1, 2026, and completion date of April 30, 2030. This basic science research grant funds investigations into the metabolic role of beige adipocytes in whole-body energy expenditure...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $372,400 to Nova Southeastern University to conduct research comparing the therapeutic potential of three compounds - tirzepatide, retatrutide, and crocetin - in mitigating Alzheimer's-like pathology in a mouse model of comorbid Alzheimer's disease and obesity/prediabetes. The 3-year study, running from December 2024 to November 2027, will assess the impact of these interventions on...
- The University of California, San Diego (UCSD) was awarded a $1,698,323 Project Grant from the National Institute on Aging (CFDA 93.866 Aging Research) to develop and validate a mouse model for Alzheimer's disease in Down syndrome (DS-AD). The goal is to create a genetically modified mouse that replicates key pathological features of DS-AD, including amyloid plaques, congophilic angiopathy, and neurofibrillary tangles. In the initial R61 phase, the researchers will demonstrate feasibility,...
A VALIDATED MOUSE MODEL OF BROWN FAT TARGETING - ABSTRACT/PROJECT SUMMARY MICE AND HUMAN PHYSIOLOGY ARE DEEPLY AFFECTED BY BROWN FAT THROUGH ITS CONTROL OF METABOLIC HOMEOSTASIS AND PRODUCTION OF SIGNALING MOLECULES. AS SUCH, BROWN FAT SPECIFIC GENETIC MODIFICATIONS IN MICE HAVE ARISEN AS A TRULY RELEVANT TOOL TO UNDERSTAND BROWN FAT ROLE IN CONTROLLING PHYSIOLOGY WITH APPLICATIONS IN AN ARRAY OF ORGAN SYSTEMS. FOR THIS, CRE-RECOMBINASE DRIVERS UNDER CONTROL OF THE UCP1 PROMOTER HAVE BEEN USED. IN THIS PROPOSAL, WE SHOW THAT THE MOST COMMONLY USED MOUSE MODEL OF BROWN FAT TARGETING IS THE SOURCE OF SOME PREVIOUSLY UNNOTICED NEGATIVE EFFECTS. THUS, OUR PRELIMINARY DATA SUPPORTS AN UNMET CRITICAL NEED TO GENERATE A NEW MOUSE MODEL TO TARGET MATURE BROWN ADIPOCYTES IN AN EFFICIENT AND SAFE MANNER. FOR THESE REASONS, THE MAIN GOALS OF THIS APPLICATION ARE TO GENERATE (AIM 1), VALIDATE (AIM 2) AND MAKE WIDELY AVAILABLE (AIM 3) A NEW MODEL OF BROWN FAT TARGETING. FOR THIS, WE WILL USE AN INNOVATIVE BUT VALIDATED CRISPR/CAS9 TARGETING TECHNIQUE TO INSERT CRE-RECOMBINASE DRIVEN BY A DEFINED UCP1 PROMOTER INTO A SAFE HARBOR LOCATION. NEXT, WE WILL USE CRE-MEDIATED LINEAGE TRACING TECHNIQUES TO ADDRESS ITS CELLULAR SPECIFICITY. DUE TO THE BROAD INTEREST IN BROWN FAT BIOLOGY, THIS MOUSE MODEL IS ANTICIPATED TO BE BROADLY USED BY SCIENTISTS IN AN ARRAY OF FIELDS OF INTEREST TO MULTIPLE NIH INSTITUTES. THIS NEW MOUSE MODEL OF BROWN FAT TARGETING IS EXPECTED TO HAVE A POSITIVE IMPACT AS A STEP FORWARD TOWARDS DEVELOPING BETTER PRECLINICAL MOUSE MODELS. WE WILL MAKE OUR NEW MODEL AVAILABLE TO THE COMMUNITY THROUGH A MOUSE REPOSITORY. FOR THESE REASONS, THIS PROPOSAL IS DIRECTED TO THE FOA PAR-21-167, "DEVELOPMENT OF ANIMAL MODELS AND RELATED MATERIALS FOR RESEARCH".
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | ($213k) | 2/4/26 | ||
| Not listed | $0 | 11/21/25 | ||
| Not listed | $0 | 11/21/25 | ||
| Not listed | $200.6k | 7/23/25 | ||
| Not listed | $200.6k | 7/23/25 |